Synairgen Share Discussion Threads

[bobaxe1] 06/4/2020 12:29

And proves nebulizer is a fantastic way to administer dode

[likya123] 06/4/2020 12:25

Then it's a great job that the drug Synairgen is using is faster acting and has proven to be more effective (in other studies) than Alpha interferon.

I believe our resident expert agrees.

[torreskid] 06/4/2020 12:17

Likya,
good research, but sadly it uses Alpha interferon (even the nebulised form)

Anyway all science/research with different therapies is priceless in this crisis

[torreskid] 06/4/2020 11:59

MAKENDON,

I have been in for a while, just that I'm fed up of the exuberance of some expecting news and sudden rises in this company. Any movement will be news driven, and I dont expect any major news till rns stating study completed, and results will be published etc.

Any investor will be in this for the results of the study, nothing else (similar to any oil drill in virgin territory)

As it stands, trading this share is not very attractive.

All imho

[bobaxe1] 06/4/2020 11:51

When the American markets wake up will we be expecting a lot of buying due to the Stanford University info

[74tom] 06/4/2020 11:40

DEMG certainly looking interesting, have taken some for a trade - should be no reason why it can't back to 2p+?

[monkeywench1] 06/4/2020 11:23

This RNS Reach from July 2019.

I found the ` rapid point of care test` interesting as it picked up coronavirus.

Phase II Clinical Trial Update in Patients with COPD



~ Clinical trial data to date shows impact of viruses on COPD patients



Southampton, UK - 24 July 2019: Synairgen (LSE: SNG), the respiratory drug discovery and development company, today announces an update on the Company's wholly-owned inhaled interferon beta (IFN-beta) programme, currently in a Phase II clinical trial, which is aimed at countering the adverse effects of common cold and influenza viruses in patients with chronic obstructive pulmonary disease (COPD).

The trial is progressing well in 15 centres around the UK and is scheduled to complete in the winter 2019-2020 virus season.

Prof. Tom Wilkinson, Chief Investigator for the trial, said: "COPD exacerbations caused by cold and influenza viruses represent a significant health risk, particularly in the winter virus season. Patients with COPD exacerbations are the second most likely group of patients to be hospitalised in England for unplanned events.

"With no effective broad-spectrum antiviral treatment on the market, Synairgen's inhaled IFN-beta may provide a novel approach for COPD patients, with the potential to greatly improve the patient's defences against viral infection, reduce exacerbations, increase quality of life and reduce hospitalisations."

An analysis of all the patients dosed to date, as a single group regardless of treatment (the study will not be unblinded until the end of the trial), shows that cold and flu infections are having a considerable impact on symptoms in COPD patients, as assessed using the validated Breathlessness, Cough and Sputum Score (BCSS). A mean decrease in BCSS score > 1 represents substantial symptomatic improvement. As we are seeing an increase in mean BCSS score >2, we have the potential to demonstrate a significant treatment effect. These changes contrast with the most recent asthma trial, where colds had less impact on patients.

The Company is also pleased to report that the rapid point-of-care test, being used to confirm that a patient has a viral infection, is ensuring that only the correct patients are being enrolled. The test ensures that only those patients for whom IFN-beta therapy may be effective are being dosed, thereby increasing the chance of the drug showing a beneficial effect. To date, approximately 35% of patients presenting with symptoms have tested positive for a viral infection. Viruses detected include rhinovirus, influenza, RSV, parainfluenza and coronavirus infections.

Richard Marsden, CEO of Synairgen, said: "Aided by the rapid point-of-care test, the trial is successfully capturing marked changes in COPD symptoms in patients with confirmed common cold and influenza virus infections. We have previously shown that inhaled IFN-beta boosts the lungs' antiviral defences in COPD patients and the magnitude of the symptom changes being observed so far in the current trial puts us in a good position to determine the potential benefit of inhaled IFN-beta in this patient population."

[nobbygnome] 06/4/2020 11:21

For those who benefitted from my DEMG tip the week before last, well it is about to take off again IMHO so is worth a look.

[bobaxe1] 06/4/2020 11:16

Has anyone sent the results to prof Tom Wilkinson!

[nobbygnome] 06/4/2020 11:08

>> likya

The result in 11 patients does indeed look significant. Of course it is uncontrolled and is interferon alpha I suspect but nevertheless a positive sign that SNG001 may well be beneficial.

[likya123] 06/4/2020 11:03

Again from lse board...

Again Richard is confident..


listen to it all but pay attention at 3:40min

[bobaxe1] 06/4/2020 11:01

(medRxiv)SARS-CoV-2Danoprevir/r +/- Nebulized Interferon x 4-12 daysObservational11Moderate PCR-confirmed COVID-19 penumonia (SaO2>=94%; PaO2/FiO2

[bobaxe1] 06/4/2020 10:57

Libya that's amazing info. Some trail were abject failures The one using interferon 1b performed very well

[cambourne] 06/4/2020 10:49

Come on!!!!! Yes

[likya123] 06/4/2020 10:25

Morning Nobby, what are your thoughts on this post?

From lse board...



If you scroll down now to observational 11
Danoprevir/r +/- Nebulized Interferon x 4-12 days
Read last sentence; All 11 patients becamse afebrile, had improved respiratory synptoms, radiological improvement, and negative PCRs.
Now its not our trial SNG001 but they use nebulised ifn and seems very positive,
Should rerate from current level 
GLA

[likya123] 06/4/2020 09:18

Interestingly, very hard to buy even smaller amounts just now..

Anyone else notice the 10k buyer loading up this morning?

A TR1 would add a little more smoke to the fire...

[makendon] 06/4/2020 09:17

Torreskid, interesting response. If you’re not in before the RNS announcement, you’ll miss the launch.

[likya123] 06/4/2020 09:16

Moving up...

[torreskid] 06/4/2020 09:12

peachie, yes cos most are impatient

not much will happen til second half of May....just check back daily at 7:55 for the rare rns, otherwise enjoy the warm weather

[peachie 74] 06/4/2020 09:02

The daily chart here is getting monotonous !
Has this become a day traders playground atm ?

[hazl] 06/4/2020 08:36

2504 thank goodness for clarity.

[cambourne] 06/4/2020 08:33

Come on SNG, get those inhalers made. SNG have £4 million for supply chain ready to get the inhalers manufactured. Sounds pretty confident to me

[shauncurt2] 06/4/2020 08:19

hxxps://covdb.stanford.edu/search/?study=clinical-studies

On this list it seems there has already been a nebulised ifn observation (maybe ifn alpha)alongside danoprivir. Results look encouraging I think??